BR0114754A - Compostos não-imidazóis - Google Patents

Compostos não-imidazóis

Info

Publication number
BR0114754A
BR0114754A BR0114754-4A BR0114754A BR0114754A BR 0114754 A BR0114754 A BR 0114754A BR 0114754 A BR0114754 A BR 0114754A BR 0114754 A BR0114754 A BR 0114754A
Authority
BR
Brazil
Prior art keywords
compounds
allergy
formula
congestion
methods
Prior art date
Application number
BR0114754-4A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of BR0114754A publication Critical patent/BR0114754A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSTOS NãO-IMIDAZóIS". São descritos pela presente invenção novos compostos de fórmula I: Também, são descritos as composições farmacêuticas que compreendem os compostos de fórmula I. São também descritos métodos de tratamento de diversas doenças ou condições doentias, tais como, por exemplo, alergia, respostas das vias aéreas induzidas por alergia e congestão (por exemplo, congestão nasal) usando os compostos de fórmula I. São também descritos métodos de tratamento de diversas doenças ou condições doentias, tais como, por exemplo, alergia, respostas das vias aéreas induzidas por alergia e congestão (por exemplo, congestão nasal) usando os compostos de fórmula I em combinação com um antagonista de receptor H~ 1~.
BR0114754-4A 2000-10-17 2001-10-15 Compostos não-imidazóis BR0114754A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24090100P 2000-10-17 2000-10-17
PCT/US2001/032151 WO2002032893A2 (en) 2000-10-17 2001-10-15 Piperidine compounds as anti-allergic

Publications (1)

Publication Number Publication Date
BR0114754A true BR0114754A (pt) 2003-07-01

Family

ID=22908389

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0114754-4A BR0114754A (pt) 2000-10-17 2001-10-15 Compostos não-imidazóis

Country Status (30)

Country Link
US (3) US6720328B2 (pt)
EP (2) EP1326858B1 (pt)
JP (2) JP4093859B2 (pt)
KR (1) KR100567266B1 (pt)
CN (2) CN1243751C (pt)
AR (1) AR035497A1 (pt)
AT (2) ATE312833T1 (pt)
AU (2) AU2002215355B2 (pt)
BR (1) BR0114754A (pt)
CA (1) CA2424664C (pt)
CY (2) CY1105227T1 (pt)
DE (2) DE60115937T2 (pt)
DK (2) DK1571145T3 (pt)
EC (1) ECSP034559A (pt)
ES (2) ES2320008T3 (pt)
HK (2) HK1052935B (pt)
HU (1) HUP0303835A3 (pt)
IL (1) IL155031A0 (pt)
MX (1) MXPA03003529A (pt)
NO (1) NO325997B1 (pt)
NZ (1) NZ524857A (pt)
PE (1) PE20020507A1 (pt)
PL (1) PL361978A1 (pt)
PT (1) PT1571145E (pt)
RU (2) RU2301231C2 (pt)
SI (1) SI1326858T1 (pt)
SK (1) SK4672003A3 (pt)
TW (2) TWI258474B (pt)
WO (1) WO2002032893A2 (pt)
ZA (1) ZA200302521B (pt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
GB2373186A (en) * 2001-02-23 2002-09-18 Astrazeneca Ab Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation
EP1373251A2 (en) * 2001-03-13 2004-01-02 Schering Corporation Non-imidazole compounds as histamine h3 antagonists
AR036881A1 (es) * 2001-10-15 2004-10-13 Schering Corp Un proceso para la preparacion de 4-(piperidil)(2-piridil)metanona-(e)-o-metiloxima y sales
US7105505B2 (en) 2002-04-18 2006-09-12 Schering Corporation Benzimidazole derivatives useful as histamine H3 antagonists
MXPA04010172A (es) 2002-04-18 2005-02-03 Schering Corp 1-(4-piperidinil)benzimidazolonas como antagonistas de histamina h3).
ATE344798T1 (de) * 2002-06-24 2006-11-15 Schering Corp Als histamin-h3-antagonisten geeignete indolderivate
US8673924B2 (en) 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
PT1537116E (pt) 2002-09-04 2010-09-03 Schering Corp Pirazolopirimidinas adequadas para o tratamento de doenças cancerosas
MXPA05007485A (es) 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
WO2004066960A2 (en) * 2003-01-28 2004-08-12 Schering Corporation Combination of h1, h3 and h4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
JP2006528939A (ja) 2003-04-23 2006-12-28 グラクソ　グループ　リミテッド ピペラジン誘導体ならびに神経および精神疾患の治療のためのその使用
ATE370135T1 (de) * 2003-07-18 2007-09-15 Glaxo Group Ltd Substituierte piperidine als histamin-h3- rezeptorliganden
US20060030550A1 (en) * 2004-08-04 2006-02-09 Lithgow Theodore L Pharmaceutical formulations
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
MX2007016523A (es) * 2005-06-20 2008-03-06 Schering Corp Piperidinas sustituidas ligadas a carbono y derivados de las mismas utiles como antagonistas de hsitamina h3.
MX2008000115A (es) 2005-06-20 2008-03-18 Schering Corp Derivados de piperidina utiles como antagonistas de histamina h3.
EP1931665A1 (en) * 2005-09-20 2008-06-18 Schering Corporation 1-[[1-[(2-amin0-6-methyl-4-pyridinyl)methyl]-4-flu0r0-4-piperidinyl,]carbonyl]-4-[2-(2-pyridinyl)-3h-imidaz0[4, 5-b]pyridin-3-yl]piperidine useful as histamine h3 antagonist
PE20071162A1 (es) * 2005-12-21 2007-11-30 Schering Corp Combinacion de un antagonista/agonista inverso de h3 y un supresor del apetito
BRPI0620255A2 (pt) * 2005-12-21 2011-11-08 Schering Corp uso de agentes redutores de colesterol e/ou antagonista/agonista inverso do receptor de h3
US7879880B2 (en) 2005-12-21 2011-02-01 Schering Corporation Substituted aniline derivatives useful as histamine H3 antagonists
KR20080087833A (ko) * 2005-12-21 2008-10-01 쉐링 코포레이션 히스타민 ｈ３ 길항제로서 유용한 페녹시피페리딘 및 이의유사체
MX2008009354A (es) 2006-01-18 2008-09-30 Schering Corp Moduladores de receptores cannabinoides.
CN101674831A (zh) * 2007-03-02 2010-03-17 先灵公司 用于治疗糖尿病或疼痛的哌啶基哌啶和哌嗪基哌啶
NZ582249A (en) * 2007-06-28 2012-06-29 Intervet Int Bv Substituted piperazines as cb1 antagonists
CA2702933C (en) * 2007-10-17 2012-12-18 Sanofi-Aventis Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof
PT2205558E (pt) * 2007-10-17 2012-11-02 Sanofi Sa Amidas de n-fenil-pirrolidinilmetilpirrolidina substituídas e sua utilização terapêutica como moduladores do receptor h3 da histamina
RU2477719C2 (ru) * 2007-10-17 2013-03-20 Санофи-Авентис Замещенные n-фенилбипирролидинкарбоксамиды и их терапевтическое применение
RS52235B (en) * 2007-10-17 2012-10-31 Sanofi N-PHENYL-BIPYROLIDINE CARBOXAMIDES SUBSTITUTED AND THE THERAPEUTIC USES
US20090221648A1 (en) * 2007-12-21 2009-09-03 Abbott Laboratories Compositions for treatment of cognitive disorders
US8383657B2 (en) * 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
US8771643B2 (en) 2008-01-04 2014-07-08 Schabar Research Associates Llc Use of analgesic potentiating compounds to potentiate the analgesic properties of an analgesic compound
EP2318388A2 (en) 2008-07-23 2011-05-11 Schering Corporation Tricyclic spirocycle derivatives and methods of use thereof
WO2010045306A2 (en) 2008-10-16 2010-04-22 Schering Corporation Azine derivatives and methods of use thereof
US20110245267A1 (en) 2008-12-19 2011-10-06 Schering Plough Corporation Piperidine and piperazine derivatives and methods of use thereof
US8283360B2 (en) 2008-12-19 2012-10-09 Merck Sharp & Dohme Corp. Bicyclic heterocyclic derivatives and methods of use thereof
RU2558141C2 (ru) * 2009-04-22 2015-07-27 Янссен Фармацевтика Нв Гетероароматические и ароматические пиперазинилазетидиниламиды в качестве ингибиторов моноацилглицеринлипазы
CA2764830A1 (en) 2009-06-16 2010-12-23 Schering Corporation Novel [3,2-c] heteroaryl steroids as glucocorticoid receptor agonists, compositions and uses thereof
AR078320A1 (es) 2009-09-04 2011-11-02 Biogen Idec Inc Derivados nitrogenados heterociclicos inhibidores de tirosinquinasas de bruton(btk), formulaciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades autoinmunes, inflamatorias y canceres.
CA2787248C (en) * 2010-01-22 2016-03-01 Taiho Pharmaceutical Co., Ltd. Piperazine compound having a pgds inhibitory effect
JP5941916B2 (ja) 2010-09-22 2016-06-29 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
CN105315267B (zh) * 2014-07-30 2019-06-04 江苏恩华药业股份有限公司 一种酰胺类衍生物及其应用
JP6895378B2 (ja) 2015-01-06 2021-06-30 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１ｐ１受容体に関連する状態の処置方法
EP3939965A1 (en) 2015-06-22 2022-01-19 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders
CA3031443A1 (en) 2016-07-21 2018-01-25 Biogen Ma Inc. Succinate of pyrimidinyl derivatives and solid forms thereof as bruton's tyrosine kinase inhibitors
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
CN110105263A (zh) * 2019-05-13 2019-08-09 常州大学 一种阿米卡星中间体的合成方法
US11331307B2 (en) 2020-07-15 2022-05-17 Schabar Research Associates, Llc Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6062590A (en) 1989-07-07 1991-02-06 Schering Corporation Pharmaceutically active compounds
US5807872A (en) 1992-12-16 1998-09-15 Schering Corporation Imidazoylalkyl substituted with a six membered nitrogen containing heterocyclic ring
US5633250A (en) 1991-12-18 1997-05-27 Schering Corporation Imidazoylalkyl substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
JPH07121939B2 (ja) 1991-12-18 1995-12-25 シェリング・コーポレーション 窒素含有４または５員複素環で置換されたイミダゾリルまたはイミダゾイルアルキル化合物
WO1995014007A1 (en) 1993-11-15 1995-05-26 Schering Corporation Phenyl-alkyl imidazoles as h3-receptor antagonists
WO1997019074A1 (en) * 1995-11-17 1997-05-29 Hoechst Marion Roussel, Inc. Substituted 4-(1h-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
MY116130A (en) 1996-08-16 2003-11-28 Schering Corp Treatment of upper airway allergic responses
US5869479A (en) 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
US5990147A (en) 1997-11-07 1999-11-23 Schering Corporation H3 receptor ligands of the phenyl-alkyl-imidazoles type
US6034251A (en) 1997-11-07 2000-03-07 Schering Corporation Phenyl-alkyl-imidazoles
TW421645B (en) * 1997-11-07 2001-02-11 Schering Corp H3 receptor ligands of the phenyl-alkyl-imidazoles type
CA2346227A1 (en) * 1998-10-09 2000-04-20 Schering Corporation Composition and method for treating allergic diseases
US6100279A (en) 1998-11-05 2000-08-08 Schering Corporation Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
EP1373251A2 (en) 2001-03-13 2004-01-02 Schering Corporation Non-imidazole compounds as histamine h3 antagonists
US7105505B2 (en) * 2002-04-18 2006-09-12 Schering Corporation Benzimidazole derivatives useful as histamine H3 antagonists
MXPA04010172A (es) * 2002-04-18 2005-02-03 Schering Corp 1-(4-piperidinil)benzimidazolonas como antagonistas de histamina h3).
ATE344798T1 (de) * 2002-06-24 2006-11-15 Schering Corp Als histamin-h3-antagonisten geeignete indolderivate
WO2004069338A1 (en) * 2003-01-31 2004-08-19 Schering Corporation Use of combinations of h1 and h3 histamine receptor antagonists for the preparation of a medicament for the treatment of allergic skin and allergic ocular conditions

Also Published As

Publication number Publication date
EP1326858B1 (en) 2005-12-14
JP2004511553A (ja) 2004-04-15
ATE420863T1 (de) 2009-01-15
US20080119487A1 (en) 2008-05-22
SK4672003A3 (en) 2003-11-04
CN1803795B (zh) 2010-05-12
ECSP034559A (es) 2003-06-25
DE60115937T2 (de) 2006-06-29
US7300941B2 (en) 2007-11-27
CY1105227T1 (el) 2010-03-03
AR035497A1 (es) 2004-06-02
EP1326858A2 (en) 2003-07-16
DK1571145T3 (da) 2009-05-04
KR100567266B1 (ko) 2006-04-03
US6720328B2 (en) 2004-04-13
ATE312833T1 (de) 2005-12-15
CN1803795A (zh) 2006-07-19
DK1326858T3 (da) 2006-05-08
CA2424664A1 (en) 2002-04-25
JP2007145866A (ja) 2007-06-14
PL361978A1 (en) 2004-10-18
ES2320008T3 (es) 2009-05-18
HUP0303835A2 (hu) 2004-03-01
NO20031744D0 (no) 2003-04-15
AU1535502A (en) 2002-04-29
ZA200302521B (en) 2004-06-30
ES2250500T3 (es) 2006-04-16
RU2301231C2 (ru) 2007-06-20
HK1052935B (zh) 2006-05-19
US20040097513A1 (en) 2004-05-20
HK1081182A1 (en) 2006-05-12
CN1243751C (zh) 2006-03-01
EP1571145B1 (en) 2009-01-14
JP4093859B2 (ja) 2008-06-04
TW200510368A (en) 2005-03-16
KR20030036931A (ko) 2003-05-09
HUP0303835A3 (en) 2009-08-28
TWI292399B (en) 2008-01-11
US20030045519A1 (en) 2003-03-06
CA2424664C (en) 2008-12-23
PT1571145E (pt) 2009-04-07
SI1326858T1 (sl) 2006-04-30
HK1052935A1 (en) 2003-10-03
PE20020507A1 (es) 2002-06-25
MXPA03003529A (es) 2003-08-07
EP1571145A1 (en) 2005-09-07
CY1110262T1 (el) 2015-01-14
WO2002032893A3 (en) 2002-08-22
IL155031A0 (en) 2003-10-31
DE60115937D1 (de) 2006-01-19
NZ524857A (en) 2004-12-24
WO2002032893A2 (en) 2002-04-25
AU2002215355B2 (en) 2006-09-14
TWI258474B (en) 2006-07-21
NO20031744L (no) 2003-06-14
CN1469873A (zh) 2004-01-21
DE60137461D1 (de) 2009-03-05
RU2007104096A (ru) 2008-08-10
NO325997B1 (no) 2008-09-01

Similar Documents

Publication Publication Date Title
BR0114754A (pt) Compostos não-imidazóis
MY131890A (en) Piperidine compounds
BR0313176A (pt) Composições de pirazol úteis como inibidores de gsk-3
BR0313041A (pt) Compostos; composições farmacêuticas; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação dos receptores de cb1; e uso de compostos
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
NO20022095L (no) Heterocyklisk substituerte pyrazoloner
BRPI0519398A2 (pt) compostos de piridina para o tratamento de doenÇas mediadas por prostaglandina
BR0208338A (pt) Derivados de piridina
BRPI0512974A (pt) novos derivados de hidantoìna para o tratamento de doenças obstrutivas das vias aéreas
DE60215000D1 (de) DIHYDROPYRROLOi1,2-AöINDOL- UND TETRAHYDROPYRIDOi1,2-AöINDOLDERIVATE ALS PROSTAGLANDIN REZEPTOR ANTAGONISTEN
BR0313676A (pt) Derivados de pirimidina e uso destes como moduladores cb2
SE0001899D0 (sv) New compounds
BRPI0410418A (pt) fenil quinolinas e seu uso como moduladores do receptor de estrogênio
MY137535A (en) New pyrrolidinium derivatives
TR200302242T2 (tr) Protein kinaz önleyicileri olarak pirolopirimidinler
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
BR0210028A (pt) Agentes antibacterianos
BR0208741A (pt) Derivados de piperidina
BRPI0413094A (pt) derivados de quinolina e seu uso em terapia
BR9811093A (pt) Piridinas substituìdas com 2-amino-6-(4-fenóxi 2-substituìdo)
BR0015821A (pt) Derivados de pirimidina
BRPI0409436A (pt) compostos de 4-fenil-piperidina e a sua utilização como moduladores de receptores de opióides
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BRPI0406596A (pt) Métodos para tratar a dor articular e melhorar o sono utilizando um agonista/antagonista de estrogênio
SE0102716D0 (sv) Novel compounds

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: CONFORME ARTIGO 10O DA RESOLUCAO 124/06, CABE SER ARQUIVADO REFERENTE AO NAO RECOLHIMENTO DA 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.